On this page
This comparison is usually written to make one side look foolish, and it deserves better. Thailand versus the United States for stem cell treatment is not a story about American patients missing out, nor about Thai clinics cutting corners — it is a difference in how much proof a regulator requires before something may be sold.
The actual difference
In the United States, cell preparations that are more than minimally manipulated are regulated as drugs. A drug requires approval, and approval requires trial evidence of safety and efficacy for a specific indication.
Culture expansion — growing cells over weeks to reach a therapeutic dose — places almost every treatment discussed on this site into that category.
So for most of these treatments the American comparison is not between a high price and a low one. It is between a price and unavailability outside a clinical trial.
See regulation in Thailand for the other side of that.
What is available in the United States
Approved haematopoietic stem cell transplantation, which is established hospital medicine for blood and immune disorders and has been for decades — see HSCT versus MSC infusion.
A small number of approved cell and gene therapy products for specific indications.
Clinical trials, which are genuinely available and frequently overlooked. Participation costs little or nothing, and for several conditions a registered trial is a more defensible route than a commercial infusion abroad.
And a domestic unregulated clinic sector, which is where much of the documented harm in this field has occurred — so “available in America” does not always mean “approved in America” either. Enforcement there has been uneven, which is worth knowing before treating the US as a uniformly stricter environment.
The argument for treatment in Thailand
Access to treatments that are not purchasable at home, at prices substantially below American medical costs generally.
Shorter waits, and an established medical travel infrastructure for international patients — see international patients.
For several indications the evidence is genuinely early rather than absent, and a patient who has exhausted standard care may reasonably weigh an early-evidence option — see what the evidence levels mean.
Those are real arguments, and none of them requires pretending the evidence is stronger than it is.
There is a further one that is rarely stated but genuine: some people want to have tried something. That is a human reason rather than a clinical one, and it is more honest to name it than to dress it up as an evidence argument.
The argument against
The evidence bar that makes these treatments unavailable in the US exists for a reason, and it is not protectionism. It is the standard that keeps ineffective products off the market generally.
Follow-up is harder across continents. If something goes wrong three weeks after you fly home, the clinic that treated you is eight time zones away.
Your own doctor may be unwilling or unable to manage complications from a treatment they did not recommend and cannot verify — see adverse events.
And insurance generally covers none of it, including complications. The exposure there can exceed the treatment cost several times over if hospital care becomes necessary.
Cost, honestly framed
Thai medical costs are lower across the board, for the same reasons they are lower for dentistry or orthopaedic surgery — staff, facilities and overheads.
But comparing a Thai price against an American price for the same treatment is often comparing against a number that does not exist, because the treatment cannot be sold there.
The honest comparison is a Thai price against the cost of standard care at home plus the option of a free clinical trial — see the cost page.
Flights, accommodation and time away from work belong in that sum too, particularly for autologous treatment where the schedule can mean two trips or a stay of several weeks.
What a US patient should check first
Whether a registered clinical trial exists for your condition. This is the step most often skipped and the one most likely to produce both treatment and evidence.
What standard care you have not yet exhausted. For osteoarthritis specifically, structured exercise therapy has evidence comparable to cell therapy and is rarely completed properly — see osteoarthritis.
What your insurer says about complications arising from elective treatment abroad, in writing, before booking anything.
And whether a domestic clinic is offering you the same thing without the flight. The US unregulated sector is substantial, and some patients travel for a treatment available forty minutes from home — at which point the comparison is not Thailand against America at all, but one unapproved product against another.
Bringing treatment home
Whatever you have, take the documentation. Product details, batch identifiers, cell type, dose, route and dates. “Stem cells” is not information a doctor at home can act on.
Expect some scepticism, and understand where it comes from — a physician asked to manage a complication from an unapproved product they cannot identify is in a genuinely difficult position, with no product information, no batch record and no way to know what was given.
Arriving with paperwork rather than a brand name makes that conversation substantially easier.
A fair summary
Thailand offers access; the United States offers a higher evidence bar. Neither is straightforwardly better, and which matters more depends on your condition, what you have already tried, and how you weigh an uncertain benefit against a certain cost.
What would not be fair is a page telling you the FDA is the obstacle between you and recovery. For most indications the obstacle is that the evidence is not there yet, and no amount of regulatory reform in either country would change that.
See the main treatment page and the research library to make that judgement yourself.
Frequently asked questions
Why can I not get this in the US?
Most expanded cell preparations are regulated as drugs there, and a drug needs approval supported by trial evidence for a specific indication.
Does that mean the FDA is wrong?
It means the FDA requires more proof before something may be sold. That standard is what keeps ineffective products off the market generally.
Is it cheaper in Thailand?
Yes, though for many treatments the American price does not exist at all, so the comparison is between a price and unavailability.
Are there US trials I could join?
Often yes, and this is the step most people skip entirely. Participation usually costs little or nothing, gives you monitored treatment, and adds to the evidence base rather than only drawing on it.
Will my US insurer cover it?
Almost certainly not, including complications. Get that confirmed in writing before booking rather than after.
What should I bring home?
Everything — cell type, source, dose, route, batch identifiers and dates. Your own doctor cannot act on the phrase “stem cells”.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.